Drugs / NGR-hTNF
NGR-hTNF
Trials 18 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 15 trials | ||||||
| Phase 1 | NCT00878111 | Apr 2009 → Feb 2017 | cancer | AGC Biologics S.p.A. | Completed | No outcome recorded |
| Phase 1 | NCT00483093 | Jul 2007 → Jun 2010 | cancer | AGC Biologics S.p.A. | Completed | No outcome recorded |
| Phase 1 | NCT00305084 | Feb 2006 → May 2007 | cancer | AGC Biologics S.p.A. | Completed | No outcome recorded |
| Phase 1 | NCT00419328 | Mar 2005 → Sep 2007 | — | AGC Biologics S.p.A. | Completed | No outcome recorded |
| Phase 1 | NCT00098943 | Sep 2004 → Nov 2007 | colorectal cancer, head and neck cancer, kidney cancer | European Organisation for Research and Treatment of Cancer - EORTC | Completed | No outcome recorded |
| Phase 212 trials | ||||||
| Phase 2 | NCT03536039 | Jan 2016 → Jan 2019 | diffuse large B-cell lymphoma | Andres J. M. Ferreri | Completed | No outcome recorded |
| Phase 2 | NCT03804866 | Mar 2013 → Dec 2016 | ovarian cancer | AGC Biologics S.p.A. | Completed | No outcome recorded |
| Phase 2 | NCT01358071 | Jun 2011 → Dec 2016 | ovarian cancer | AGC Biologics S.p.A. | Completed | No outcome recorded |
| Phase 2 | NCT01358084 | Mar 2011 → Dec 2018 | malignant pleural mesothelioma | AGC Biologics S.p.A. | Completed | No outcome recorded |
| Phase 2 | NCT00484341 | Oct 2010 → May 2016 | soft tissue sarcoma | AGC Biologics S.p.A. | Completed | No outcome recorded |
| Phase 2 | NCT00994097 | Jul 2009 → Mar 2017 | non-small cell lung carcinoma | AGC Biologics S.p.A. | Completed | No outcome recorded |
| Phase 2 | NCT00484432 | Nov 2008 → Jun 2016 | ovarian cancer | AGC Biologics S.p.A. | Completed | No outcome recorded |
| Phase 2 | NCT00675012 | Dec 2007 → Dec 2010 | colon carcinoma | AGC Biologics S.p.A. | Completed | No outcome recorded |
| Phase 2 | NCT00484276 | May 2007 → Mar 2013 | malignant pleural mesothelioma | AGC Biologics S.p.A. | Completed | No outcome recorded |
| Phase 2 | NCT00483509 | Feb 2007 → Sep 2010 | small cell lung carcinoma | AGC Biologics S.p.A. | Completed | No outcome recorded |
| Phase 2 | NCT00484211 | Dec 2006 → Nov 2011 | hepatocellular carcinoma | AGC Biologics S.p.A. | Completed | No outcome recorded |
| Phase 2 | NCT00483080 | Dec 2006 → Jun 2009 | colorectal cancer | AGC Biologics S.p.A. | Completed | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT01098266 | Apr 2010 → Apr 2014 | malignant pleural mesothelioma | AGC Biologics S.p.A. | Completed | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 22 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | NGR-hTNF | “PURPOSE: This phase I trial investigating the vascular targeting agent NGR-hTNF aimed to determine” PMID 20145168 ↗ Feb 2010 |
| Known as | asparagine-glycine-arginine-human tumor necrosis factor alpha | “Phase II study of asparagine-glycine-arginine-human tumor necrosis factor alpha, a selective vascular targeting agent, in previously treated patients with malignant pleural...” PMID 20406925 ↗ Apr 2010 |
| Known as | asparagine-glycine-arginine-human tumour necrosis factor | “The NGR-hTNF (asparagine-glycine-arginine-human tumour necrosis factor) is able to promote antitumour immune responses and to improve the intratumoural doxorubicin uptake by...” PMID 22644293 ↗ May 20121“asparagine-glycine-arginine-human tumour necrosis factor (NGR-hTNF)” PMID 20855468 ↗ Sep 2010 |
| Modality | Protein / enzyme biologic | “Targeted therapy with tumor necrosis factor combined with a fusion protein may stop the growth of solid tumors by stopping blood flow to the tumor.” NCT00098943 ↗ |
| Route | Intravenous | “Patients receive tumor vasculature-targeted tumor necrosis factor alpha (NGR-TNF) IV over 1 hour on day 1.” NCT00098943 ↗ |